Genmab A/S (GMAB)
| Market Cap | 20.02B |
| Revenue (ttm) | 800.90M |
| Net Income (ttm) | 323.28M |
| Shares Out | 64.30M |
| EPS (ttm) | 0.51 |
| PE Ratio | 61.51 |
| Forward PE | 74.63 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $31.24 |
| Previous Close | $31.75 |
| Change ($) | -0.51 |
| Change (%) | -1.61% |
| Day's Open | 31.37 |
| Day's Range | 31.02 - 31.46 |
| Day's Volume | 1,492,847 |
| 52-Week Range | 16.24 - 44.83 |
Company Announcement
Company Announcement
Company Announcement
Company Announcement
Company Announcement
Company Announcement
Hijacking the immune system to destroy cancer with bispecific antibodies could be a lucrative business for biotech stocks like Amgen, Genmab and Regeneron Pharmaceuticals. The post The $12 Bil...
Genmab (NASDAQ: GMAB) and Seagen Inc (NASDAQ: SGEN) have jointly announced the submission of a marketing application with the FDA, seeking accelerated approval for tisotumab vedotin for the tr...
Company Announcement
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U...
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and p...
Company Announcement
Media Release Copenhagen, Denmark, January 6, 2021
Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.
Company Announcement
Media Release COPENHAGEN, Denmark, Jan. 04, 2021
Genmab is a well-managed and vast European biopharma R&D giant. Its partnered products and self-owned pipelines are vast.
Company Announcement
Company Announcement
Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations
If you are looking for potential value opportunities amid U.S.-listed equities, picking stocks that meet the following three criteria represent a solid starting point, in my opinion:
Media Release Copenhagen, Denmark, November 10, 2020 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. and CFO Anthony Pagano, will present an update at the Jeff...
Company Announcement
Media Release Copenhagen, Denmark, November 5, 2020
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call Transcript
November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020
Media Release Copenhagen, Denmark, November 4, 2020
Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020
Media Release Copenhagen, Denmark, October 14, 2020
Genmab: Still A Rising Star In Biotech, But Legal Dispute May Slow Down Growth Trajectory In The Near Term
Copenhagen, Denmark; September 30, 2020 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the...
Shares in Danish biotech firm Genmab fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson over royalty payments for its key cancer ...
Copenhagen, Denmark; September 22, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with Janssen Bi...
BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm...
These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.
Media Release Copenhagen, Denmark, September 10, 2020
About GMAB
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovar... [Read more...]
| Industry Biotechnology | Founded 1999 |
| CEO Jan van de Winkel | Employees 781 |
| Stock Exchange NASDAQ | Ticker Symbol GMAB |
Financial Performance
In 2019, Genmab A/S's revenue was 5.37 billion, an increase of 77.39% compared to the previous year's 3.03 billion. Earnings were 2.17 billion, an increase of 47.15%.
Analyst Forecasts
According to 7 analysts, the average rating for Genmab A/S stock is "Buy." The 12-month stock price forecast is 42.43, which is an increase of 35.82% from the latest price.